+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis)



Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis)



American Heart Journal 127(3): 483-494



The purpose of this study was to determine if there are any morphologic characteristics of lesions that renarrow (that is, restenotic lesions) following successful coronary balloon angioplasty that are different from their appearance pretreatment or from the appearance of nonrestenotic lesions that might provide some new insight into the restenosis phenomenon. The study population consisted of 653 patients (778 lesions) with 6 months of angiographic follow-up (94% angiographic follow-up rate) who were participating in the Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) study. Detailed quantitative angiographic measurements, including the mean diameter of the vessel segment (in millimeters) that was subjected to balloon dilation, were performed preangioplasty, postangioplasty, and at follow-up using the cardiovascular angiographic analysis system to provide some objective measurement of the actual extent of luminal changes in the months following coronary balloon angioplasty. Two different approaches for restenosis were used: (1) static criterion of > 50% diameter stenosis at follow-up and (2) dynamic criteria of > or = 0.40 or > or = 0.72 mm change in minimal lumen diameter between postangioplasty and follow-up. Both approaches identified more severe stenosis to be a typical feature for restenotic lesions before angioplasty compared with nonrestenotic lesions. No differences were observed in lesion length, balloon-inflated vessel segment, or roughness index before angioplasty between the groups. Conflicting data were found for the amount of atherosclerotic plaque, symmetry index, and curvature index. The restenotic lesion at follow-up compared with its initial appearance gave conflicting results depending on which approach was used. The dynamic criteria illustrate that the reference diameter and the mean diameter of the entire segment dilated are reduced during follow-up. Two messages emerge from the study: (1) the restenosis process clearly involves the apparent normal vessel wall adjacent to the actual lesion, probably in response to the unavoidable injury caused by balloon dilatation and (2) the use of percentage diameter stenosis measurements depending on the assumptions of normality for a reference segment will therefore underestimate the true extent of the restenosis process and should be replaced in clinical angiographic studies by absolute luminal measurements.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046727219

Download citation: RISBibTeXText

PMID: 8122593


Related references

Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 86(1): 100-110, 1992

Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Journal of Cardiovascular Pharmacology 22 Suppl 4: S45-S57, 1993

Angiotensin-converting enzyme inhibitor in a human model of restenosis. MERCATOR ("Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis") Study Group. Basic Research in Cardiology 88 Suppl 1: 169-182, 1993

Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries: Results from the Multicenter American Research Trial with cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis (MARCATOR). Journal of the American College of Cardiology 27(1): 1-7, 1996

Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. Journal of the American College of Cardiology 25(2): 362-369, 1995

Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups. European Heart Journal 16(10): 1331-1346, 1995

Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group. American Journal of Cardiology 78(2): 221-224, 1996

Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site. A quantitative angiographic study in consecutive patients undergoing a third angioplasty procedure for a second restenosis. Circulation 88(3): 969-974, 1993

Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. Journal of the American College of Cardiology 12(3): 616-623, 1988

Incidence of restenosis 30 days after successful percutaneous transluminal coronary angioplasty a quantitative coronary angiographic study in 100 consecutive patients. European Heart Journal 6(ABSTR SUPPL 1): 61, 1985

Incidence of restenosis 30 and 60 days after successful percutaneous transluminal coronary angioplasty a quantitative coronary angiographic study in 200 consecutive patients. American Heart Association Monograph (114): III-140, 1985

Effects and chronology of coronary restenosis after percutaneous transluminal coronary angioplasty. Quantitative angiographic analysis at 1, 2, 3, 4 and 5 months. Archives des Maladies du Coeur et des Vaisseaux 82(2): 177-184, 1989

Effectiveness of Probucol in preventing restenosis after percutaneous transluminal coronary angioplasty in small sized coronary arteries A subgroup analysis of the Probucol angioplasty restenosis trial. Journal of the American College of Cardiology 29(2 SUPPL A): 418A-419A, 1997

Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. Journal of the American College of Cardiology 30(4): 855-862, 1997

Relationship between restenosis and successive angiographic findings of the coronary artery lesions after percutaneous transluminal coronary angioplasty. Medical Journal of Kinki University 17(3): 383-403, 1992